SCHEMBL4674095

SCHEMBL4674095

O=C(C=C(O)c1nc[nH]n1)c1cc(Cc2ccccc2C(F)(F)F)co1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
HTT P42858 1/20 0.35
NR3C2 P08235 1/20 0.34
SNCA P37840 1/20 0.34
GPR52 Q9Y2T5 1/20 0.33
FFAR1 O14842 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
ABL1 P00519 1/20 0.33
SRC P12931 1/20 0.33
NR1H2 P55055 1/20 0.32
NR1H3 Q13133 1/20 0.32
NTRK1 P04629 1/20 0.32
MAOB P27338 2/20 0.32
MAOA P21397 1/20 0.32
ALOX5 P09917 1/20 0.32
ALOX5AP P20292 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4670907 0.87 BRS3 (0.35) ARKDM4ENR3C2SNCANTRK1
SCHEMBL4676464 0.85 BRS3 (0.35) ARKDM4EALDH1A1SNCALMNA
SCHEMBL4679147 0.85 PTGER4 (0.35) HCAR2LMNA
SCHEMBL4676336 0.84 AR (0.35) ARKDM4EALDH1A1TDP1HTT
SCHEMBL4671631 0.83 BRS3 (0.38) ARKDM4ETDP1NR3C2SNCA
SCHEMBL4678499 0.83 NR3C2 (0.35) ARKDM4EALDH1A1TDP1HTT
SCHEMBL4671979 0.83 KDM5A (0.38) KDM4EALDH1A1NR3C2SNCAFFAR4
SCHEMBL4673646 0.83 NR4A2 (0.38) KDM4ENR3C2GPR52FFAR1FFAR4
SCHEMBL4675329 0.83 PTPN11 (0.32) KDM4ELMNANPSR1
SCHEMBL4673057 0.82 AR (0.35) ARKDM4ENR3C2GPR52FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 AR 10/4885KDM4E 947/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.